JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

145.91

+2.06%↑

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

7.53 1.76

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

7.28

Max

7.75

Pagrindiniai rodikliai
By Trading Economics
Pajamos	5.7M -30M
Pardavimai	3.1M 34M
Pelno marža	-89.424
Darbuotojai	182
EBITDA	5.2M -35M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+223.89% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-11-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	76M 759M
Ankstesnė atidarymo kaina	5.77
Ankstesnė uždarymo kaina	7.53

Naujienos nuotaikos

By Acuity

50%

153 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-21 23:55; UTC

Karštos akcijos

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

2025-10-21 23:49; UTC

Uždarbis

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

2025-10-21 21:40; UTC

Uždarbis

Waste Connections 3Q Revenue Rises

2025-10-21 21:14; UTC

Uždarbis

Pagrindinės rinkos jėgos

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

2025-10-21 21:05; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

2025-10-21 20:57; UTC

Įsigijimai, susijungimai, perėmimai

DraftKings to Launch Prediction Markets Platform

2025-10-21 20:38; UTC

Uždarbis

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

2025-10-21 20:35; UTC

Uždarbis

Capital One 3Q Sales, Profit Jump

2025-10-21 20:32; UTC

Uždarbis

Texas Instruments 3Q Revenue Up on Growth Across End Markets

2025-10-21 23:44; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-21 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

2025-10-21 23:39; UTC

Rinkos pokalbiai

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

2025-10-21 23:36; UTC

Rinkos pokalbiai

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

2025-10-21 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Scentre Says This Forms Part of Capital Management Strategy

2025-10-21 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

2025-10-21 22:54; UTC

Įsigijimai, susijungimai, perėmimai

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

2025-10-21 21:09; UTC

Rinkos pokalbiai

Uždarbis

Netflix Creators Have Started Using AI in Production -- Market Talk

2025-10-21 20:58; UTC

Rinkos pokalbiai

Uždarbis

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

2025-10-21 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-21 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-10-21 20:43; UTC

Uždarbis

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

2025-10-21 20:41; UTC

Uždarbis

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

2025-10-21 20:33; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

2025-10-21 20:33; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

2025-10-21 20:32; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

2025-10-21 20:32; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

2025-10-21 20:32; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

2025-10-21 20:32; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

2025-10-21 20:31; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

2025-10-21 20:29; UTC

Uždarbis

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

223.89% į viršų

12 mėnesių prognozė

Vidutinis 24 USD 223.89%

Aukščiausias 34 USD

Žemiausias 16 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

153 / 371 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.